Month: September 2026

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising.

NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) — via AINewsWire — SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) today announces its placement in an editorial published by AINewsWire (“AINW”), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

To view the full publication, “The GPS-Denied Economy: Why Navigation Is the Next Infrastructure Layer,” please visit: https://ibn.fm/BKDUj

GPS can no longer be trusted. Lost-signal incidents jumped 220% between 2021 and 2024, and the trend is accelerating. The drone industry’s default fix — bolting more sensors, chips and software onto every aircraft — works one airframe at a time and stalls the moment a fleet grows past a handful.

SPARC AI Inc. takes the opposite approach. Its Overwatch Positioning Network moves positioning off the aircraft entirely: A drone sends the telemetry it already generates to SPARC AI’s servers and gets latitude, longitude and time back in under a second. No new hardware. No added weight. One network serving an entire fleet at once. In a defense, security and commercial drone market projected to exceed $100 billion over the next decade, that software-defined, per-device subscription model puts SPARC AI at the front of next-generation geolocation and targeting.

About SPARC AI Inc.

SPARC AI is a defense technology company solving one of the most critical challenges in modern autonomous systems: accurate navigation and targeting when GPS is unavailable. The company’s AI-powered platform transforms the low-cost inertial sensors already inside commercial drones into precision instruments without additional hardware, external signals, or complex integration. SPARC AI’s software-only approach makes GPS-denied capability for target acquisition and navigation accessible at the price point and scale that modern drone operations demand, from single platforms to fleets of thousands.

For further information, please visit the company’s website at www.SPARCAI.co

NOTE TO INVESTORS: The latest news and updates relating to SPAIF are available in the company’s newsroom at https://ibn.fm/SPAIF

About AINewsWire

AINewsWire (AINW) is a specialized communications platform with a focus on the latest advancements in artificial intelligence (“AI”), including the technologies, trends and trailblazers driving innovation forward. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, AINW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, AINW brings its clients unparalleled recognition and brand awareness.

AINW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from AINewsWire, text “AI” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit www.AINewsWire.com

DISCLAIMER: AINewsWire (AINW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by AINW are solely those of AINW. Readers of this Article and content agree that they cannot and will not seek to hold liable AINW for any investment decisions by their readers or subscribers. AINW is a news dissemination and financial marketing solutions provider and NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, AINW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

AINW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan” or “planned,” “will” or “should,” “expected,” “anticipates,” “draft,” “eventually,” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and AINW undertakes no obligation to update such statements.

Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or re-published: 
https://www.AINewsWire.com/Disclaimer

AINewsWire
Austin, Texas
www.AINewsWire.com
512.354.7000 Office
Editor@AINewsWire.com

AINewsWire is powered by IBN

Protocol Submitted for IRB Review at a Leading Cancer Research Institution, Advancing the Study Toward Site Initiation

MIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) — MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced that, following review and comments from the U.S. Food and Drug Administration (FDA), the Phase 2a protocol evaluating Ketamir-2 in chemotherapy-induced peripheral neuropathy (CIPN) has been submitted for Institutional Review Board (IRB) review at a leading cancer research institution.

MIRA incorporated the FDA’s feedback into the protocol and is targeting site initiation in the first quarter of 2027, subject to completion of IRB review and other routine site activation requirements. The study represents Ketamir-2’s first clinical evaluation in patients with CIPN and is designed to generate initial efficacy and dose-response data while further characterizing safety and tolerability.

“We are entering an important stage for Ketamir-2 as we prepare to evaluate the drug for the first time in patients with persistent CIPN,” said Erez Aminov, CEO of MIRA. “This marks the transition from establishing safety and pharmacokinetics in healthy volunteers to evaluating Ketamir-2’s potential therapeutic effect in patients.”

About the Phase 2a Study

The randomized, double-blind, placebo-controlled, three-period crossover study will enroll adults with moderate-to-severe persistent CIPN. Participants will receive Ketamir-2 at 300 mg and 600 mg, as well as placebo, in a defined treatment sequence across three seven-day treatment periods separated by 13-day washout periods, allowing each participant to serve as their own control.

The study will evaluate the safety, tolerability, efficacy, and dose-response relationship of oral Ketamir-2, including its effect on post-chemotherapy neuropathic pain intensity. Additional assessments will evaluate CIPN-related symptoms and functional status, as well as potential central nervous system adverse effects.

The study builds on MIRA’s completed Phase 1 clinical program in healthy volunteers, in which Ketamir-2 demonstrated a favorable safety, tolerability, and pharmacokinetic profile, with no serious adverse events or dose-limiting toxicities reported. The Phase 2a study will be conducted under MIRA’s active Investigational New Drug (IND) application.

Addressing a Significant Unmet Need in Neuropathic Pain

CIPN is a painful and potentially persistent complication of certain commonly used chemotherapies that can continue long after cancer treatment has ended. Treatment options remain limited, and there are currently no FDA-approved therapies specifically indicated for CIPN. Existing treatment approaches offer limited options for managing painful CIPN, underscoring the need for new therapies specifically developed for this condition.

Ketamine has demonstrated analgesic activity in neuropathic pain through modulation of the NMDA receptor pathway, supporting the therapeutic relevance of this mechanism. However, its broader use as a chronic treatment can be constrained by intravenous administration, dissociative and other neuropsychiatric effects, monitoring requirements, and its Schedule III controlled-substance status.

Ketamir-2 is being developed as an oral NMDA receptor modulator designed to engage this therapeutically relevant pathway while potentially overcoming key limitations associated with ketamine. Ketamir-2 is orally administered; its Phase 1 pharmacokinetic profile supports once-daily dosing, and it is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA).

“There is a strong scientific rationale for targeting NMDA receptor signaling in neuropathic pain,” said Itzchak Angel, Ph.D., Chief Scientific Advisor of MIRA. “Ketamine has provided important clinical validation of this pathway, but its properties can limit its practicality for chronic use. Ketamir-2 was designed as an oral NMDA receptor modulator with high selectivity and a differentiated pharmacologic profile, and we believe this Phase 2a study will provide an important first opportunity to determine whether this profile can translate into meaningful pain reduction in patients with persistent CIPN.”

While CIPN is the initial patient population being evaluated in Phase 2a, MIRA believes that positive clinical evidence in CIPN could support the evaluation of Ketamir-2 across additional neuropathic pain conditions where NMDA receptor signaling may play a role. The Company views CIPN as a potential clinical entry point into the broader neuropathic pain market.

October Scientific Presentation and BioJapan Participation

MIRA expects to present Ketamir-2 at the International Conference on Addiction and Psychiatry in Tokyo, Japan, on October 5–6, 2026, where an abstract titled “An Oral Selective NMDA Modulator for Chemotherapy-Induced Peripheral Neuropathy—Phase 1 Safety, Pharmacokinetics, and Clinical Development Update” has been accepted for oral presentation by Dr. Itzchak Angel, MIRA’s Chief Scientific Advisor.

MIRA also expects to participate in BioJapan in October as the Company continues licensing and strategic partnership discussions around Ketamir-2 and its broader pipeline.

About Ketamir-2

Ketamir-2 is MIRA Pharmaceuticals’ proprietary oral NMDA receptor modulator in clinical development for neuropathic pain. The compound is designed to selectively modulate the NMDA receptor PCP binding site with low binding affinity and limited off-target receptor activity.

MIRA holds exclusive worldwide rights to Ketamir-2 and is pursuing intellectual property protection across major global pharmaceutical markets.

About MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics. The Company’s pipeline includes Ketamir-2 for chemotherapy-induced peripheral neuropathy (CIPN), which has completed Phase 1 and is advancing toward Phase 2a under an active IND; MIRA-55, an investigational oral drug candidate for inflammatory pain; and SKNY-1, an investigational oral drug candidate for obesity. Following scientific review, the U.S. Drug Enforcement Administration has determined that Ketamir-2, MIRA-55, and SKNY-1 are not classified as controlled substances.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally may be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,” “intend,” “seek,” “target” and other words of similar meaning, although not all forward-looking statements include these words. Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, efficacy, anticipated clinical development, commercialization prospects, market opportunity, and future development of MIRA-55, SKNY-1, Ketamir-2, and the Company’s other product candidates.

These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s current beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions, and the other risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K and the Company’s subsequent filings with the U.S. Securities and Exchange Commission (“SEC”).

Forward-looking statements contained in this press release speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Investors are cautioned not to place undue reliance on these forward-looking statements. Additional information regarding these and other risks and uncertainties is contained in the Company’s filings with the SEC, including its Annual Report on Form 10-K and subsequent filings, available at www.sec.gov and in the Investors section of the Company’s website at www.mirapharmaceuticals.com. Forward-looking statements should be considered in light of these risks and uncertainties.

Investor and Media Contact

Krystina Quintana
MIRA Pharmaceuticals
info@mirapharma.com 
(786) 432-9792

Majority-owned Nevada company to expand 8-inch and 12-inch wafer sorter and AOI output for global market projected to reach $9.7 billion by 2030

Subject to finalization of definitive agreements, TechForce Advanced Manufacturing’s operation is expected to begin production and contribute initial revenue to the Company during Q4 2026, corresponding with the Company’s fiscal second quarter

LOS ANGELES, Sept. 17, 2026 (GLOBE NEWSWIRE) — via IBN — Nightfood Holdings, Inc. (OTCQB: NGTF) (“Nightfood” or the “Company”), doing business as TechForce Robotics, today announced the formation of TechForce Advanced Manufacturing, Inc. (“TechForce Advanced Manufacturing”), a Nevada corporation established to pursue a strategic advanced-manufacturing partnership with JUN LONG MACHINE INDUSTRIAL CO., LTD. (“JUN LONG”). The establishment of TechForce Advanced Manufacturing marks a key initial step in the Company’s planned commercial expansion into the semiconductor manufacturing equipment industry.

TechForce Advanced Manufacturing is intended to be owned 51% by Nightfood and 49% by JUN LONG. Nightfood will provide strategic oversight, commercialization support, public-company infrastructure and access to capital-raising resources. JUN LONG will contribute technical know-how, manufacturing expertise, product-development capabilities and customer relationships.

Calendar Q4 2026 Production and Revenue Target
Both parties anticipate finalizing and signing the definitive agreement within the next several weeks. TechForce Advanced Manufacturing is preparing additional manufacturing capacity, suppliers, engineering support and customer-integration resources to address near-term demand.

JUN LONG currently holds purchase orders from key customers, representing existing demand that TechForce Advanced Manufacturing expects to begin fulfilling upon completion of the definitive agreement. This order backlog supports the Company’s target of commencing production and generating initial revenue in calendar Q4 2026, subject to completion of the definitive agreement, customer orders and applicable qualification requirements. The timing and amount of revenue will depend on production schedules, delivery, customer acceptance and applicable U.S. GAAP requirements.

Expanding Wafer Sorter and AOI Production
The partnership’s immediate commercial focus is expanding production of an automated Wafer Sorter and Automated Optical Inspection (“AOI”) system designed for both 8-inch and 12-inch silicon wafers. The system combines robotic wafer handling, automated inspection and grading, identification-based sorting, front-side optical character recognition (“OCR”) and optional Semiconductor Equipment Communication Standard (“SECS”) factory connectivity.

The system supports inspection, identification, transfer and sorting within semiconductor and Chip-on-Wafer-on-Substrate (“CoWoS”) related advanced-packaging production. CoWoS enables processors, chiplets and high-bandwidth memory to be integrated into high-performance packages used in artificial intelligence and advanced computing systems.

According to an independent industry report, the global semiconductor wafer inspection equipment market is projected to grow from approximately $7.05 billion in 2026 to approximately $9.67 billion by 2030.

About Nightfood Holdings, Inc. (d/b/a TechForce Robotics)
Nightfood Holdings, Inc., doing business as TechForce Robotics, is an advanced robotics and automation company focused on delivering intelligent, scalable solutions for industrial and commercial applications. The Company integrates robotics, artificial intelligence and software-driven systems to optimize operations, improve efficiency and enable next-generation automation.

TechForce Robotics partners with organizations to design and deploy customized robotic solutions that address evolving operational requirements.

Learn more: www.techforcerobotics.com

About TechForce Advanced Manufacturing
TechForce Advanced Manufacturing, Inc. is a Nevada corporation formed to develop, manufacture, commercialize, install and support semiconductor automation and inspection systems. Its initial focus is expanding Wafer Sorter and AOI production for wafer-based semiconductor and CoWoS-related advanced-packaging applications, while pursuing future applications supporting emerging Chip-on-Panel-on-Substrate (“CoPoS”) manufacturing processes.

Forward-Looking Statements
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect,” “plan,” “project,” “target,” “will” and similar expressions identify forward-looking statements.

These statements include, among other things, expectations concerning the completion and timing of definitive agreements; the proposed ownership and operating structure of TechForce Advanced Manufacturing; the expansion of manufacturing capacity; customer demand and orders; the commencement of production; the timing and amount of revenue recognition; and the development of additional semiconductor automation and advanced-packaging applications.

Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by these forward-looking statements. Such statements are based on the Company’s current expectations and are subject to risks and uncertainties. The Company undertakes no obligation to update or revise any forward-looking statements as a result of new information, future events or otherwise, except as required by law. Investors are encouraged to review the Company’s filings with the Securities and Exchange Commission for additional information regarding applicable risks and uncertainties.

Investor Relations, Media Relations and Corporate Communications
Investor Relations
ir@nightfoodholdings.com

Media Relations
media@nightfoodholdings.com

Corporate Communications:
IBN.Ai
Austin, Texas
www.IBN.Ai
512.354.7000 Office
Editor@IBN.Ai

Year-to-date console sales exceed full-year console sales in seven of the past 10 years, putting Nuwellis on pace for one of its strongest years in console placements

MINNEAPOLIS, Sept. 17, 2026 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced continued commercial momentum for its Aquadex SmartFlow^® system, with 31 consoles sold year-to-date in 2026. The Company’s year-to-date console performance already exceeds full-year console sales in seven of the past 10 years and puts Nuwellis on pace for one of its top three years for console sales. The expanding installed base comes alongside broader commercial momentum, including 26% year-over-year U.S. revenue growth during the first half of 2026.

“Selling 31 consoles at this point in the year is an important indicator of the commercial progress we are making to expand our installed base of Aquadex systems,” said Mike McCormick, Nuwellis President and Chief Executive Officer. “We are particularly encouraged by our year-to-date performance in that it is being driven by hospitals that recognize the level of patient care associated with Aquadex. This shows that they are making the informed, deliberate decision to incorporate Aquadex into their fluid-management programs.”

Each additional Aquadex console expands the Company’s installed base and creates opportunities for recurring utilization of the Company’s single-use blood circuits. The Aquadex SmartFlow system consists of a console, catheter, and disposable blood circuit set used to provide controlled ultrafiltration therapy. As the installed base expands and utilization increases, Nuwellis believes console placements can support continued growth in recurring consumable revenue.

Notably, the Company’s highest historical console-placement years included the COVID-19 period, when hospitals expanded access to fluid-removal technologies in response to extraordinary critical-care demand. Nuwellis’ 2026 performance is being achieved in a normalized hospital environment and reflects continued adoption of Aquadex in the U.S. across the Company’s core pediatric, critical-care, and heart-failure markets.

The 2026 console momentum builds upon Nuwellis’ broader commercial performance. During the first half of 2026, the Company reported U.S. revenue growth of 26% compared with the prior-year period, with growth across pediatrics, critical care, and heart failure. The Company believes the combination of an expanding installed base, increasing consumable utilization, and continued commercial execution positions the Company to build a larger and more durable recurring-revenue business.

McCormick continued, “Our objective is to build productive Aquadex programs where clinicians use the technology to treat patients effectively when diuretics fail. Expanding the installed base creates the foundation for increasing utilization, recurring circuit revenue and broader adoption of Aquadex therapy.”

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ strategy includes expanding its portfolio through internally developed technologies and strategic commercial partnerships that broaden its presence across acute and chronic critical care. For more information, visit www.nuwellis.com.

Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.

For further information, please contact:

Investor Relations:
CORE IR
ir@nuwellis.com

Media Contact:
CORE PR
media@nuwellis.com

MARKHAM, Ontario, Sept. 17, 2026 (GLOBE NEWSWIRE) — Sienna Senior Living Inc. (“Sienna” or the “Company“) (TSX: SIA) announced today that it has entered into a purchase agreement to acquire Stonemont On the Park (“Stonemont”), a 305-suite retirement residence in Ottawa, Ontario.

The property opened in 2024 and is approximately 99% occupied. Stonemont is conveniently located in Ottawa’s east end and offers high-quality amenities as well as above- and below-grade parking.

The gross purchase price for Stonemont is approximately $170.7 million, or $560,000 per suite. The transaction includes an additional $10.0 million earnout contingent upon exceeding certain financial targets and is expected to close in Q4 2026, subject to regulatory and customary closing conditions. The Company intends to finance the acquisition with available cash on hand and its credit facilities.

“With the addition of Stonemont, we are further expanding Sienna’s retirement platform in a key market,” said Nitin Jain, President and Chief Executive Officer. “Following this transaction, we will have added approximately $1.2 billion of assets through acquisitions and developments since 2025. We continue to build on this momentum with a strong acquisition pipeline and Sienna’s $625 million joint venture partnership with Fiera Infrastructure to accelerate long-term care redevelopments. These opportunities allow us to further scale our platform, enhance the experience of Sienna’s residents and team members, while creating long-term value for our shareholders.”

About Sienna Senior Living

Sienna Senior Living Inc. (TSX: SIA) offers a full range of seniors’ living options, including independent living, assisted living and memory care under its Aspira retirement brand, long-term care, and specialized programs and services. Sienna’s approximately 15,500 employees are passionate about cultivating happiness in daily life. For more information, please visit www.siennaliving.ca.

Forward-Looking Statements

Certain of the statements contained in this news release are forward-looking statements and are provided for the purpose of presenting information about management’s current expectations and plans relating to the future. Readers are cautioned that such statements may not be appropriate for other purposes. These statements generally use forward-looking words, such as “anticipate,” “continue,” “could,” “expect,” “may,” “will,” “estimate,” “believe,” “goals”, “target” or other similar words and are based on the Company’s expectations, estimates, forecasts and projections. These statements are subject to significant known and unknown risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such statements and, accordingly, should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not such results will be achieved. The forward-looking statements in this news release are based on information currently available and what management currently believes are reasonable assumptions. The Company does not undertake any obligation to publicly update or revise any forward-looking statements except as may be required by applicable law.

FOR FURTHER INFORMATION, PLEASE CONTACT:

David Hung
Chief Financial Officer and Executive Vice President, Investments
(905) 489-0258
david.hung@siennaliving.ca

Nancy Webb
Executive Vice President, Corporate Affairs and Marketing
(905) 477-4006 ext. 3030
nancy.webb@siennaliving.ca

DENVER, Sept. 17, 2026 (GLOBE NEWSWIRE) — Pure Cycle Corporation (Nasdaq Capital Market: PCYO) (“Pure Cycle”, “we”, “us” or “our”) announced today that Mark W. Harding, President and Chief Executive Officer, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.

“We are pleased to participate in the Lytham Partners Fall 2026 Investor Conference,” commented Mr. Harding. “The virtual format allows us to reach a broad audience of institutional and individual investors and to detail our value proposition combining water and land development here in Colorado. Pure Cycle continues to drive shareholder value with development of our master planned community, Sky Ranch, while expanding Rangeview’s municipal water and wastewater system that serves Sky Ranch and other customers throughout our service area.”

Company Webcast

Pure Cycle’s webcast presentation can be viewed beginning at 1:45 p.m. ET on Tuesday, September 29, 2026. The webcast can be accessed at https://app.webinar.net/Xk3b9WmM5gE or by visiting the conference website at https://lythampartners.com/fall2026/. A replay will be available following the event.

1×1 Meetings

Management will participate in virtual one-on-one meetings with investors throughout the conference. To arrange a meeting, please contact Lytham Partners at 1×1@lythampartners.com or register for the event at https://lythampartners.com/fall2026invreg/.

Company Information

Pure Cycle continues to strengthen its operations, build its balance sheet, and drive recurring revenues. We operate in three distinct business segments, each of which complements the others. At our core, we are a vertically integrated wholesale water and wastewater service provider. In 2017, we launched our land development segment, which develops master planned communities on land we own and to which we provide water and wastewater services. In 2021, we launched our newest line of business, the rental of single-family homes located at Sky Ranch, which provides long-term recurring revenues, furthers our land development operations, and adds more customers to our water resource segment.

Additional information, including our recent press releases and SEC filings, is available at www.purecyclewater.com, or you may contact our President, Mark W. Harding, or our CFO, Marc Spezialy, at 303-292-3456 or info@purecyclewater.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are all statements, other than statements of historical facts, included in this press release that address activities, events or developments that we expect or anticipate will or may occur in the future, such as statements about the following: our participation in the Lytham Partners Fall 2026 Investor Conference; our development activities at Sky Ranch; and the continued expansion of our regional water and wastewater system. The words “anticipate,” “likely,” “may,” “should,” “could,” “will,” “believe,” “estimate,” “expect,” “plan,” “intend,” “potential” and similar expressions are intended to identify forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain and involve risks and uncertainties that could cause actual results to differ materially. Factors that could cause actual results to differ from projected results include, without limitation: home mortgage interest rates, inflation, trade policies, tariffs, and other factors impacting the housing market and home sales; the risk factors discussed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended August 31, 2025; and those factors discussed from time to time in our press releases, public statements and documents filed or furnished with the U.S. Securities and Exchange Commission.

SOURCE: Pure Cycle Corporation

Industry Veterans Appointed in New York and Boston, Augmenting Venture Banking and Venture Capital Coverage Nationwide

ST. LOUIS, Sept. 17, 2026 (GLOBE NEWSWIRE) — Stifel Financial Corp. (NYSE: SF) today announced the addition of three senior leaders to its Venture Banking business, further solidifying its presence across the East Coast venture ecosystem.

Chris Morrison, Matt Scott, and Arianne Perry, each of whom previously held senior roles at Silicon Valley Bank (“SVB”), join Stifel to expand Venture Banking and Venture Capital Coverage efforts in Boston and New York. Their appointments strengthen the firm’s ability to serve the banking and financing needs of venture capital-backed technology companies, their founders, and investors.

Chris Morrison joins as a Managing Director, focused on Venture Banking in the Boston market. Matt Scott joins as a Managing Director, focused on Venture Banking in the New York City market. Arianne Perry joins as a Managing Director, Venture Capital Coverage, focused on expanding the firm’s investor coverage presence in New York City and the East Coast.

“We are pleased to welcome Chris, Matt, and Arianne to Stifel as we continue to build our Venture Banking business,” said Stifel Chairman and CEO Ron Kruszewski. “The innovation economy is an important growth opportunity for Stifel. Their experience and relationships strengthen our ability to serve entrepreneurs and investors with the full capabilities of Stifel, from early stage financing through the public markets and beyond.”

Prior to joining Stifel, Chris Morrison spent 15 years at SVB, including three years leading the growth stage practice and more than a decade in credit and venture lending at the bank.

Most recently, Matt Scott worked at TriplePoint Capital, where he focused on private credit investments in leading high-growth technology companies. Before this, he led SVB’s Enterprise Software team in New York City, served as a venture capital investor at Basecamp Fund, and served as a founder and operator at multiple venture capital-backed tech companies.

Arianne Perry previously led SVB’s East Coast Investor Coverage from New York City, providing venture capital investors with tailored financial services and supporting venture-backed technology companies with capital, credit, and banking solutions. She also spent nearly 10 years as a start-up founder and lead operator in the New York City venture ecosystem. Prior to that, she worked in various finance and investing roles at JPMorgan and Google.

“Stifel has built a differentiated Venture Banking platform that combines a deep understanding of the venture capital ecosystem with the capabilities of a broader financial services firm,” said Morrison, Scott, and Perry in a joint statement. “We look forward to partnering with founders and investors from the earliest stages of a company’s growth through pre-IPO and beyond, providing the banking, financing, and advisory solutions they need as their businesses evolve.”

The hires build on Stifel’s continued investment in its Venture Banking practice, including the recent addition of dedicated Project Finance and Life Sciences and Healthcare teams. The business now includes more than 125 client-facing professionals located in every major U.S. tech market.

Stifel’s Venture Banking practice serves more than 500 leading, high-growth companies across a diverse range of industries including artificial intelligence, climate technology, consumer technology, cybersecurity, fintech, healthcare, and more. To date, the platform has supported their innovation with more than $12 billion in loan commitments.

Stifel Company Information

Stifel Financial Corp. (NYSE: SF) is a diversified financial services firm providing wealth management, commercial and investment banking, trading, and research services to individuals, institutions, and municipalities. Founded in 1890 and headquartered in St. Louis, Missouri, the firm operates more than 400 offices across the United States and in major global financial centers. As a firm where success meets success, Stifel works closely with retail and institutional clients aiming to transform opportunities into achievement.

Stifel Bank and Stifel Bank & Trust, Members FDIC, offer a full range of consumer and commercial lending solutions, including Venture Banking and Venture Capital Coverage. To learn more about Stifel, please visit the Company’s website at Stifel.com. For global disclosures, please visit www.stifel.com/investor-relations/press-releases. 

Media Contacts

Neil Shapiro, +1 (212) 271-3447
shapiron@stifel.com

Evan Roesen, +1 (212) 271-3610
roesene@stifel.com

Investor Relations Contact
Joel Jeffrey, +1 (212) 271-3610
investorrelations@stifel.com

TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), today announced three corporate updates.

1. Change of Auditor:

The Company determined that it was in its future best interest to pursue engaging an auditor who is capable of conducting a U.S. Public Company Accounting Oversight Board (“PCAOB”) mandate. The mandate was offered to Clearhouse LLP (the “Predecessor Auditor”), which advised the Company that it was unable to accept the engagement.

Following a request for proposals from multiple audit firms, the Company decided to replace the Predecessor Auditor with Davidson & Company LLP (the “Successor Auditor”).

On September 14, 2026, the Board of Directors of the Company passed a resolution to appoint Davidson & Company LLP and accepted the resignation of the Predecessor Auditor.

The Company extends its gratitude to Clearhouse LLP for its past service and looks forward to working with Davidson & Company LLP.

2. Water Tower Research

On April 23, 2026, PharmAla entered into a Subscription Services Agreement (the “Agreement”) with Water Tower Research LLC (“WTR”), a wholly owned subsidiary of alphaDIRECT Group LLC.

Under the Agreement, WTR will provide PharmAla with company research, investor engagement and stakeholder communication and intelligence programs through the production of research reports and supporting content (collectively referred to as “WTR Content”) distributed through WTR’s proprietary digital delivery infrastructure.

PharmAla agreed to pay $58,000 (“Annual Fee”) for access to the Subscription Services, which commenced on May 15, 2026 (“Effective Date”), upon execution of this Agreement. This Agreement has a one (1) year term (the “Term”) ending on May 15, 2027. There is no equity linked compensation for WTR under the terms of the Agreement.

In connection with the Subscription Services, PharmAla will receive:

• Ongoing analyst support and coverage of Clients company which may include but is not limited to: Initiation of Coverage (“IOC”) Fireside Chats – Video Update Notes
• Management Series Reports
• Quarterly Earnings Notes
• WTR’s Small-Cap Spotlight Podcast
• Industry Notes Inclusion
• Expert Series – Video
• WTR Symposium Series Events
• Symposium Series Recap Notes  

WTR shares content through their digital delivery infrastructure, which includes their own website, social media and with direct mailing lists.

3. Oak Hill Financial Inc.

On April 21, 2026, PharmAla signed a contract with Oak Hill Financial Inc. (“Oak Hill”). Oak Hill will provide business and capital markets advisory services, including raising the Company’s profile with the investment community, and assisting dissemination of investor presentation materials.

The initial term of the agreement was two months. Following the initial term, the agreement may be extended on a month-to-month basis at the sole discretion of the Company. Upon renewal, the monthly fee will remain the same. Either party may terminate the agreement after the initial term upon five (5) business days’ written notice. The Company will pay Oak Hill a monthly advisory fee of $12,000 plus pre-approved out-of-pocket expenses.

There are no performance factors under the agreement with Oak Hill, and Oak Hill will not receive any common shares or other securities of the Company as compensation. Oak Hill has no present interest, directly or indirectly, in the Company or its securities, or any right or intent to acquire such an interest. Oak Hill is an arm’s length party to the Company.

About PharmAla

PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials as well as commercial sales in selected jurisdictions, and to develop novel drugs in the same class. PharmAla is the only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. PharmAla’s research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators.

For more information, please contact:
Nicholas Kadysh
Chief Executive Officer
PharmAla Biotech Holdings Inc.
Email: press@PharmAla.ca
Phone: 1-855-444-6362
Website: www.PharmAla.ca

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on PharmAla’s current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by PharmAla at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. The forward-looking information contained in this press release is made as of the date hereof, and PharmAla is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in PharmAla’s management’s discussion and analysis which is available on PharmAla’s profile at www.sedar.com.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

– Late-Breaking Data to Include HOPE-3 Delayed-Start and Natural History Analyses Submitted in the Recent Major Amendment to the Deramiocel BLA –

– PDUFA Target Action Date of November 22, 2026 –

SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that data from HOPE-3 and its open-label extension (OLE) of Deramiocel, the Company’s lead asset for the treatment of Duchenne muscular dystrophy (DMD), will be presented in a late-breaking poster and an oral presentation at the 31^st Annual Congress of the World Muscle Society (WMS 2026), taking place September 29 – October 3, 2026, in Hiroshima, Japan. The presentations will report skeletal muscle and cardiac outcomes through 24 months, building on the previously reported 12-month HOPE-3 results. Of the 106 patients randomized in HOPE-3, 82 reached the 24-month time point, comprising 40 originally assigned to Deramiocel and 42 to placebo.

“These HOPE-3 24-month data, along with additional analyses supporting Deramiocel’s potential safety and efficacy, were part of our recent major amendment to the Deramiocel BLA,” said Linda Marbán, Ph.D., CEO of Capricor. “We look forward to presenting these results at the World Muscle Society Congress.”

Beyond the Deramiocel program, Capricor will also present two preclinical posters from its StealthX™ exosome platform.

WMS Presentations

Title: Deramiocel slows upper limb decline in the HOPE-3 OLE: cross-phase delayed-start analysis and 2-year comparison with natural history
Presenting author: Dr. Craig McDonald, University of California, Davis
Details: Late-breaking poster session

Title: HOPE-3, a phase 3 study of deramiocel, an allogeneic cell therapy, in advanced Duchenne muscular dystrophy: evidence to support both musculoskeletal and cardiac efficacy
Presenting author: Dr. Craig McDonald
Details: Oral presentation, clinical trial updates session, October 3, 2026

Title: Engineered muscle-targeting extracellular vesicles for systemic delivery of micro-dystrophin: novel redosable strategy for Duchenne muscular dystrophy
Presenting author: Mafalda Cacciottolo, Ph.D., Capricor Therapeutics
Details: Poster session 2, DMD treatments, September 30, 2026

Title: Delivery of acid α-glucosidase by muscle-targeting extracellular vesicles: a new road for Pompe disease treatment
Presenting author: Mafalda Cacciottolo, Ph.D.
Details: Poster session 3, Glycogenoses, October 2, 2026

Copies of the presentations and posters will be added to the publications section of the Capricor website following each presentation. The full WMS 2026 program is available at https://www.wms2026.com/page/programme.

About the HOPE-3 Study

HOPE-3 is a Phase 3, randomized, double-blind, placebo-controlled trial evaluating Deramiocel in patients with Duchenne muscular dystrophy. The study enrolled 106 patients, randomized to receive Deramiocel or placebo administered intravenously every three months over a 12-month treatment period. HOPE-3 met its primary endpoint, with Deramiocel slowing decline in upper limb function by 54 percent versus placebo as measured by Performance of the Upper Limb (PUL) version 2.0 (p=0.03). One-year results were published in The Lancet in July 2026. Patients who completed the randomized portion of the study were eligible to continue receiving Deramiocel in an open-label extension.

About Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a severe, X-linked genetic disorder characterized by progressive muscle degeneration affecting the skeletal, respiratory, and cardiac muscles. It is caused by the absence of functional dystrophin, a key structural protein in muscle cells. DMD affects approximately 15,000 individuals in the United States and primarily impacts boys. Over time, deterioration of the heart muscle leads to cardiomyopathy and heart failure, the leading cause of death in DMD. There is no cure, and treatment options remain limited.

About Deramiocel

Deramiocel (CAP-1002) consists of allogeneic cardiosphere-derived cells (CDCs), a rare population of cardiac cells that have been shown in preclinical and clinical studies to exert immunomodulatory and anti-fibrotic actions in the preservation of skeletal and cardiac muscle function in muscular dystrophies such as DMD. CDCs act by secreting extracellular vesicles known as exosomes, which target macrophages and alter their expression profile to adopt a healing rather than pro-inflammatory phenotype. For the treatment of DMD, Deramiocel holds Orphan Drug, RMAT and Rare Pediatric Disease designations in the U.S., and Orphan Drug and ATMP designations in Europe. The Rare Pediatric Disease designation may qualify Capricor for a Priority Review Voucher upon approval.

About Capricor Therapeutics

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for Duchenne muscular dystrophy (DMD), evaluated in clinical studies for its potential to preserve skeletal and cardiac muscle function. Capricor is also advancing its proprietary StealthX™ exosome platform for the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of diseases. At Capricor, we are committed to delivering new therapies for patients with rare diseases. For more information, visit capricor.com and follow Capricor on Facebook, Instagram and X.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including future interactions with regulatory authorities and the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; the potential that required regulatory inspections may be delayed or not be successful which would delay or prevent product approval, revenue and reimbursement estimates, projected terms of definitive agreements, our financial position, our possible uses of existing cash and investment resources; results of securities litigation; and statements regarding our litigation with Nippon Shinyaku Co., Ltd. and NS Pharma, Inc., including the nature of the dispute, our expectations regarding any legal proceedings, and our ability to commercialize Deramiocel independent of our existing distribution agreement and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 17, 2026 and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as filed with the Securities and Exchange Commission on August 14, 2026. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

Deramiocel and Capricor’s StealthX™ exosome therapeutics are investigational and have not been approved for commercial use in any indication.

For more information, please contact:

Capricor Media Contact:
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
ckasunich@kcsa.com / rcona@kcsa.com
212.896.1241 / 516.779.2630

Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755

Agreement Reserves Approximately $53 Million of Pendergrass Manufacturing Capacity for Northern Ontario Edge AI Data Center Projects

Represents First Commercial Capacity Reservation Under Previously Announced Approximately $200 Million Utility-Scale Framework

SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) — NeoVolta Inc. (NASDAQ: NEOV) (“NeoVolta” or the “Company”), a U.S.-based energy technology company delivering scalable energy storage solutions, today announced that its majority-owned subsidiary, NeoVolta Power, LLC (“NeoVolta Power”), has entered into a binding capacity reservation agreement with Infinite Grid Capital (“IGC”) to provide battery energy storage system (“BESS”) equipment for North Ontario Edge artificial intelligence datacenter (“Edge AIDC”) projects for calendar year 2027.

Today’s announcement represents the first major commercial commitment under NeoVolta Power’s previously announced utility-scale framework with IGC, which contemplates approximately 1.1 GWh of potential BESS deployments and approximately $200 million of potential supply across multiple markets. The approximately $53M binding commitment advances the Company’s strategy of converting early utility-scale demand visibility into binding commercial relationships as its Pendergrass manufacturing platform progresses through commissioning and production-ramp activities.

“This is an important commercial milestone for NeoVolta Power and a meaningful validation of the platform we have built at Pendergrass,” said Ardes Johnson, Chief Executive Officer of NeoVolta. “The project demonstrates how our BESS manufacturing, a differentiated supply-chain strategy, and scalable energy-storage products can address the rapidly growing power-infrastructure needs of data centers and other energy-intensive customers. As we advance the production ramp at Pendergrass, our focus is on executing this initial commitment and converting additional qualified demand into binding customer orders.”

Utility-Scale Demand Validation

The capacity reservation agreement is intended to support the Northern Ontario Edge AIDC project and represents an initial commercial step within NeoVolta’s broader relationship with IGC. The relationship was previously announced as a non-binding framework spanning approximately 1.1 GWh of potential demand.

The Company believes the initial data-center-related commitment is strategically significant. Growth in artificial intelligence and data-center infrastructure is increasing the need for reliable, scalable power solutions, and BESS is expected to play an increasingly important role in supporting grid reliability, load management, and project-level energy resilience. The commitment provides commercial validation for NeoVolta Power’s utility-scale product offering and its domestic BESS manufacturing strategy.

Pendergrass Grand Opening

NeoVolta will host a grand-opening ceremony for its NeoVolta Power facility in Pendergrass, Georgia, later today. Members of NeoVolta management, key strategic partners, media, and local officials are expected to attend.

The event marks the official opening of the Company’s 210,600-square-foot facility, a purpose-built domestic BESS manufacturing platform designed to assemble commercial, industrial, and utility-scale energy-storage products. The Company’s initial Pendergrass production line is advancing through commissioning and Site Acceptance Testing, and the production ramp remains on track for the fourth quarter of calendar 2026.

NeoVolta expects to provide additional updates regarding the commissioning process, manufacturing milestones, and commercial activity as appropriate.

About Infinite Grid Capital

Infinite Grid Capital (“IGC”) is an energy infrastructure investment platform that develops and finances large-scale power projects, including battery energy storage systems, hybrid energy hubs, and dedicated power solutions for data centers across North America and selected global markets, including key U.S. power regions such as California, Texas, and the Southeastern United States. IGC focuses on building reliable and flexible energy assets that ensure continuous power for AI workloads, industrial operations, and other mission-critical facilities. Infinite Grid Capital is an existing strategic investor in NeoVolta and provides offtake origination and related advisory services in connection with NeoVolta Power’s BESS manufacturing operations.

For more information, visit www.infinitegridcapital.com.

About NeoVolta

NeoVolta is an innovator in energy storage solutions dedicated to advancing reliable, high-performance power infrastructure for residential, commercial, and utility applications. With a focus on scalable technology, domestic manufacturing, and strategic partnerships, NeoVolta is positioned to support the accelerating transition toward resilient energy systems.

For more information, visit www.neovolta.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements include statements regarding the Company’s business strategy, plans, objectives, expectations, and future operations; the anticipated timing and benefits of the Company’s manufacturing activities; the Company’s ability to execute its production ramp and achieve manufacturing and commercial milestones; anticipated customer demand, project opportunities, and order conversion; and the Company’s growth plans and future financial and operating performance.

Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, risks related to market conditions; customer demand; the Company’s ability to execute its business strategy and manufacturing plans; supply-chain availability and costs; project development, permitting, construction, and deployment activities; the availability of financing; changes in laws, regulations, tax incentives, tariffs, or trade policies; competition; and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission.

Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update or revise them, except as required by law.

Contacts

NEOV Investors
Bryan Baritot
Alliance Advisors IR
ir@neovolta.com  

NEOV Media
Email: press@neovolta.com
Phone: 800-364-5464